MiMedx Group (NASDAQ:MDXG) Rating Increased to Strong-Buy at Wall Street Zen

Key Points

• MiMedx Group received an upgrade from a "hold" to a "strong-buy" rating by Wall Street Zen, indicating positive sentiment from analysts.
• Cantor Fitzgerald raised the company's target price from $11.00 to $12.00 and assigned an "overweight" rating, suggesting potential for growth.
• MiMedx Group reported earnings of $0.10 per share, exceeding analyst expectations, with revenues of $98.61 million during the last quarter.

MiMedx Group (NASDAQ:MDXG - Get Free Report) was upgraded by Wall Street Zen from a "hold" rating to a "strong-buy" rating in a research note issued on Saturday.

Separately, Cantor Fitzgerald boosted their price target on MiMedx Group from $11.00 to $12.00 and gave the company an "overweight" rating in a research note on Thursday.

MiMedx Group Stock Performance

Shares of MiMedx Group stock traded down $0.01 during trading on Friday, reaching $7.15. The company's stock had a trading volume of 980,630 shares, compared to its average volume of 696,110. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.90 and a current ratio of 4.39. The business's fifty day moving average price is $6.44 and its 200-day moving average price is $7.24. The firm has a market cap of $1.06 billion, a price-to-earnings ratio of 34.05 and a beta of 1.79. MiMedx Group has a one year low of $5.47 and a one year high of $10.14.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.04. MiMedx Group had a return on equity of 23.03% and a net margin of 8.84%. The firm had revenue of $98.61 million for the quarter, compared to analyst estimates of $90.79 million. As a group, equities research analysts predict that MiMedx Group will post 0.3 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Paradigm Capital Management Inc. NY lifted its holdings in MiMedx Group by 0.5% during the 4th quarter. Paradigm Capital Management Inc. NY now owns 4,686,231 shares of the company's stock worth $45,082,000 after buying an additional 22,131 shares in the last quarter. Cannell Capital LLC lifted its holdings in MiMedx Group by 1.1% during the 4th quarter. Cannell Capital LLC now owns 3,639,545 shares of the company's stock worth $35,012,000 after buying an additional 40,235 shares in the last quarter. First Light Asset Management LLC lifted its holdings in MiMedx Group by 3.3% during the 1st quarter. First Light Asset Management LLC now owns 3,453,074 shares of the company's stock worth $26,243,000 after buying an additional 109,213 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in MiMedx Group by 18.4% during the 4th quarter. Renaissance Technologies LLC now owns 1,804,557 shares of the company's stock worth $17,360,000 after buying an additional 280,327 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in MiMedx Group by 15.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,802,364 shares of the company's stock worth $17,338,000 after buying an additional 238,075 shares in the last quarter. 79.15% of the stock is owned by institutional investors and hedge funds.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.